Overview

Rifaximin Versus Lactulose in Renal Failure

Status:
Unknown status
Trial end date:
2009-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Weill Medical College of Cornell University
Treatments:
Lactulose
Rifamycins
Rifaximin
Criteria
Inclusion Criteria:

- cirrhosis of liver of any etiology

- progressive renal failure

- stage 0-2 hepatic encephalopathy

Exclusion Criteria:

- pregnant women